SOURCE-LINKED STUDY SUMMARY
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Abstract summarized · Quality not appraised
- Studied
- SURPASS-5 tested once-weekly tirzepatide versus placebo added to titrated insulin glargine over forty weeks.
- Who / model
- The randomized trial enrolled adults with type 2 diabetes inadequately controlled with daily insulin glargine, with or without metformin.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- Found
- Adding tirzepatide improved glycemic control and reduced body weight versus placebo; diarrhea and nausea were more common.
- Limits
- Premature treatment discontinuation was more frequent in each tirzepatide group than with placebo.
Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary
Research findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jama.2022.0078